Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond

Oncologist

Volumn 6, Issue 2, 2001, Pages 133-146

  Esteva, Francisco J ^a   Valero, Vicente ^a   Pusztai, Lajos ^a   Boehnke Michaud, Laura ^a   Buzdar, Aman U ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biologic therapy; Breast neoplasm; Chemotherapy; Prognostic markers

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; BENDAMUSTINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVACET; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PREDNISONE; RALTITREXED; RAZOXANE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG ACTIVATION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS;

EID: 0035049886     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-2-133     Document Type: Article

References (111)

1. Cancer Statistics, 2001
2. Adjuvant systemic therapy for primary breast cancer
3. Chemotherapy for metastatic disease
4. Treatment of metastatic breast cancer
5. Treatment of breast cancer
6. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
7. Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma
8. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG
9. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
10. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy
11. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: A Southeastern Cancer Study Group Project
12. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer
13. A comparison of intermittent vs. continuous use of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: A Cancer and Leukemia Group B Study
14. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: A CALGB study
15. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
16. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
17. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
18. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
19. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
20. Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: A cross-over study
21. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
22. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin
23. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
24. Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment
25. Promotion of microtubule assembly in vitro by Taxol
26. Inactivation of Bcl-2 by phosphorylation
27. Bcl2 is the guardian of microtubule integrity
28. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
29. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
30. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer
31. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
32. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial
33. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
34. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26
35. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
36. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
37. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over
38. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: An Intergroup trial
39. Paclitaxel (Taxol) and Docetaxel (Taxotere): Not simply two of a kind
40. Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy
41. Docetaxel
42. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
43. Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
44. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
45. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
46. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
47. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
48. Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
49. A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer
50. Current status of Taxotere (docetaxel) as a new treatment in breast cancer
51. Docetaxel administered on a weekly basis for metastatic breast cancer
52. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
53. A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged 55 years
54. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
55. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine)
56. Improved therapeutic index with lower dose capecitabine in metastatic breast cancer patients
57. Vinorelbine: An overview
58. Phase II study of Navelbine in advanced breast cancer
59. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer
60. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
61. A review of the antitumour activity of vinorelbine in breast cancer
62. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
63. Phase I study of Navelbine (vinorelbine) administered by 96-hour infusion in metastatic breast cancer patients
64. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
65. Herceptin and vinorelbine for Her2-positive metastatic breast cancer: A phase II study
66. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine
67. Advanced breast cancer: A phase II trial with gemcitabine
68. Combination versus sequential single agent chemotherapy in advanced breast cancer: Associations with metastatic sites and long-term survival
69. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
70. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
71. Update: The M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma
72. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer
73. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
74. Phase III multicenter trial comparing Taxol/doxorubicin (AT) vs 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer
75. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
76. A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer
77. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety
78. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
79. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer
80. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC)
81. Docetaxel (D) in combination with doxorubicin (Dx) (AT) and with cyclophosphamide (CTX) (TAC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC): High activity and absence of cardiotoxicity
82. Phase II trial of doxorubicin and docetaxel for locally advanced and metastatic breast cancer: Preliminary results from NSABP BP-57
83. Docetaxel (Taxotere) plus doxorubicin-based combinations: The evidence of activity in breast cancer
84. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study
85. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
86. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
87. Results of a large phase III trial of Xeloda/Taxotere combination therapy vs Taxotere monotherapy in metastatic breast cancer patients
88. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer
89. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
90. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method
91. The importance of dose intensity in chemotherapy of metastatic breast cancer
92. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
93. High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer - Reply
94. Monoclonal antibody-based therapy of breast cancer
95. The Her-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
96. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
97. Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
98. Stability of Her-2/neu expression over time and at multiple metastatic sites
99. Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease
100. First-line, non-hormonal, treatment of women with Her2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-Her2 antibody)
101. Addition of Herceptin (Humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
102. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-Her2 monoclonal antibody Herceptin (H) in Her2-overexpressing (Her2+) metastatic breast cancer (MBC)
103. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
104. Final report: Weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): Analysis of efficacy by Her2 immunophenotype [immunohistochemistry (IHC)] and gene amplification (fluorescent in-situ hybridization (FISH)
105. Analysis of response to weekly 1 hour Taxol (T) plus Herceptin (H) by immunophenotypic analysis in Her-2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer
106. Herceptin in combination with chemotherapy for the treatment of metastatic breast cancer
107. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer
108. Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide (AC) and Doxorubicin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer
109. Doxorubicin and docetaxel (AT) is superior to standard doxorubicin and cyclophosphamide (AC) as first line CT for MBC: Randomized phase III trial